<DOC>
	<DOCNO>NCT01688544</DOCNO>
	<brief_summary>Ilaprazole novel proton pump inhibitor metabolize CYP3A4 2C19 . Thus genetic polymorphism CYP3A4 2C19 may effect pharmacokinetics pharmacodynamics Ilaprazole .</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Study Ilaprazole Evaluate Effect CYP Genetic Polymorphism</brief_title>
	<detailed_description>Effects genetic polymorphism pharmacokinetics pharmacodynamics measure healthy Korean volunteer</detailed_description>
	<criteria>healthy adult volunteer 20 45 year age within 20 % ideal body weight No congenital acquire chronic disease appropriate study judge examination ( hematology , chemistry , urinalysis ) , vital sign ECG result sign informed consent form prior study participation receive metabolize enzyme transporter induce inhibit drug like barbiturate within 1 month prior date first drug administration history hypersensitivity drug clinically significant allergic disease abnormal laboratory result positive result helicobacter pylorus infection Urea Breath Test alcohol drug abuser pregnant lactating donate whole blood within 60days prior study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Ilaprazole</keyword>
	<keyword>Intragastric pH</keyword>
	<keyword>Serum Gastrin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>